Mesa, Ruben http://orcid.org/0000-0001-5880-7972
Harrison, Claire
Oh, Stephen T. http://orcid.org/0000-0002-8564-5400
Gerds, Aaron T. http://orcid.org/0000-0002-3422-1309
Gupta, Vikas http://orcid.org/0000-0002-1419-8607
Catalano, John
Cervantes, Francisco
Devos, Timothy
Hus, Marek
Kiladjian, Jean-Jacques http://orcid.org/0000-0002-8121-438X
Lech-Maranda, Ewa
McLornan, Donal http://orcid.org/0000-0003-1224-091X
Vannucchi, Alessandro M.
Platzbecker, Uwe http://orcid.org/0000-0003-1863-3239
Huang, Mei
Strouse, Bryan
Klencke, Barbara http://orcid.org/0000-0002-9518-2526
Verstovsek, Srdan http://orcid.org/0000-0002-6912-8569
Article History
Received: 8 April 2022
Revised: 17 June 2022
Accepted: 23 June 2022
First Online: 22 July 2022
COMPETING INTERESTS
: Ruben Mesa has received grants or contracts from Celgene/Bristol-Myers Squibb, Incye, AbbVie, Samus, Genotech, Promedior, CTI Biopharma, Constellation, and National Cancer Institute; and consulting fees from Novartis, Sierra Oncology, LaJolla, and Constellation. Claire Harrison has received grants or contracts from Celgene/Bristol-Myers Squibb, Constellation, and Novartis; consulting fees from Keros, Galecto, AOP Orphan Pharmaceuticals, and Roche; payments or honoraria from Novartis, Celgene, CTI Biopharma, AbbVie, Janssen, and Constellation; support to attending meetings from Novartis; and has participated on Data Safety Monitoring or Advisory Boards for Galecto, CTI Biopharma, Roche, Geron, Promedior, AbbVie, AOP Orphan Pharmaceuticals, and Sierra Oncology, in addition to leadership or fiduciary roles in EHA and MPN Voice. Stephen T. Oh has received consulting fees from CTI Biopharma, Celgene/Bristol-Myers Squibb, Incyte, Blueprint Medicines, AbbVie, Sierra Oncology, Disc Medicine, Constellation, and PharmaEssentia. Aaron T. Gerds has participated in Data Safety Monitoring or Advisory Boards at Sierra Oncology, CTI Biopharma, Incyte, AbbVie, Celgene/Bristol-Myers Squibb, Morphosys, Novartis, and PharmEssentia. Vikas Gupta has received consulting fees from Novartis, Celgene/Bristol-Myers Squibb, Sierra Oncology, AbbVie, Constellation, and Pfizer; payment or honoraria from Novartis, Celgene/Bristol-Myers Squibb, and Constellation; and has participated on Data Safety Monitoring or Advisory Boards for Celgene/Bristol-Myers Squibb, Roche, AbbVie, and Pfizer. John Catalano states no conflicts of interest. Francisco Cervantes has received consulting feeds from Bristol-Myers Squibb; payment or honoraria from Pfizer; and support for attending meetings from Bristol-Myers Squibb. Timothy Devos has received consulting fees for Novartis, Celgene/Bristol-Myers Squibb, Morphosys, and AbbVie. Marek Hus states no conflicts of interest. Jean-Jacques Kiladjian has received consulting fees from Novartis, Celgene/Bristol-Myers Squibb, and AOP Orphan Pharmaceuticals; payment or honoraria from Novartis; and has participated in Data Safety Monitoring or Advisory Boards for Incyte. Ewa Lech-Maranda has participated in Data Safety Monitoring or Advisory Boards for AbbVie, Roche, Gilead, and Novartis. Donal McLornan has received research funding from Novartis; royalties from a book on myelofibrosis; payment or honoraria from Nocartis, Jazz, and AbbVie, and has participated on a Data Safety Monitoring Board for the UK ALLRIC trial. Alessandro M. Vannucchi has received payment or honoraria from Novartis, AbbVie, Celgene/Bristol-Myers Squibb, and AOP Orphan Pharmaceuticals; participated in Data Safety Monitoring and Advisory Boards with Incyte, Novartis, Celgene/Bristol-Myers Squibb, AbbVie, GlaxoSmithKline, and AOP Orphan Pharmaceuticals. Uwe Platzbecker has received consulting fees from AbbVie, Novartis, Celgene/Bristol-Myers Squibb, Janssen, Curis, and Geron; payment or honoraria from Novartis, Takeda, Celgene/Bristol-Myers Squibb, Janssen, and Jazz Pharmaceuticals; and has participated on Data Safety Monitoring or Advisory Boards for Novartis, AbbVie, and Celgene/Bristol-Myers Squibb. Mei Huang, Bryan Strouse, and Barbara Klencke are employees of and claim stock options from Sierra Oncology. Srdan Verstovsek has received consulting fees from Sierra Oncology.